Oncoimmunology

Article	Citations
Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer	98
Identification of pyroptosis-related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in colorectal cancer	93
Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies	75
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer	72
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity	70
IFN-γ-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells	67
Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer	64
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non–small-cell lung cancer	61
Ferroptosis becomes immunogenic: implications for anticancer treatments	61
Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer	60
Exosome-mediated communication between tumor cells and tumor-associated macrophages: implications for tumor microenvironment	59
Lipid-associated macrophages in the tumor-adipose microenvironment facilitate breast cancer progression	57
YKT6 , as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration	54
Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study	53
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma	49
Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity	47
Integrated analyses of m 1 A regulator-mediated modification patterns in tumor microenvironment-infiltrating immune cells in colon cancer	46
TIGIT + TIM-3 + NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related	45
Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer	44
The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis	44
Trial watch: intratumoral immunotherapy	41
Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients	41
Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma	39
Gas plasma irradiation of breast cancers promotes immunogenicity, tumor reduction, and an abscopal effect in vivo	39
Tumors exploit CXCR4 hi CD62L lo aged neutrophils to facilitate metastatic spread	39

Chronic stress promotes breast carcinoma metastasis by accumulating myeloid-derived suppressor cells through activating β-adrenergic signaling	38
Association between immune-related adverse event timing and treatment outcomes	38
Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness	38
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors	38
Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry	37
Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis	37
Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice	37
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors	37
Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs	36
Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer	36
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression	36
CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy	35
The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer	35
STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer	35
Tumor-intrinsic determinants of immunogenic cell death modalities	35
Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma	34
CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma	34
Combination of EP 4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells	34
A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer	34
Targeting stearoyl-coa desaturase enhances radiation induced ferroptosis and immunogenic cell death in esophageal squamous cell carcinoma	33
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients	33
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer	33
Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer	33
LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells	33
PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy	33
Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma	33
Trial watch: chemotherapy-induced immunogenic cell death in oncology	33
Neutrophil extracellular traps induce tumor metastasis through dual effects on cancer and endothelial cells	32
Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer	32
Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine	32
Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma	31
Novel deep learning-based survival prediction for oral cancer by analyzing tumor-infiltrating lymphocyte profiles through CIBERSORT	31
Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer	31
Cldn-7 deficiency promotes experimental colitis and associated carcinogenesis by regulating intestinal epithelial integrity	30
M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer	30
Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion	30
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer	30
Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer	29
Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12	29
PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma	29
Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis	29
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data	28
VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma	28
Characterization of immune landscape in papillary thyroid cancer reveals distinct tumor immunogenicity and implications for immunotherapy	28
Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma	28
PD-1 blockade improves the anti-tumor potency of exhausted CD3 + CD56 + NKT-like cells in patients with primary hepatocellular car	28
Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors	28
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity	28
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer	27
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma	27

PD-L2 based immune signature confers poor prognosis in HNSCC	27
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study	27
CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors	27
Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma	27
Discovery of immunogenic cell death-inducing ruthenium-based photosensitizers for anticancer photodynamic therapy	27
LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs	26
Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1	26
Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma	26
Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma	26
Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers	26
Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response	26
Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer	26
The dark side of ferroptosis in pancreatic cancer	25
TNFSF15 facilitates differentiation and polarization of macrophages toward M1 phenotype to inhibit tumor growth	25
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors	25
Single-cell profiling of infiltrating B cells and tertiary lymphoid structures in the TME of gastric adenocarcinomas	25
Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting	24
Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients	24
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure	24
Increased frequency of TIGIT + CD73-CD8 + T cells with a TOX + TCF-1low profile in patients wit	24
CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development	24
Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer	24
IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer	24
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538	24
Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An	24
Single-cell transcriptome analysis of CAR T-cell products reveals subpopulations, stimulation, and exhaustion signatures	24
Double-edged effects of interferons on the regulation of cancer-immunity cycle	24
Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma	23
Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity	23
Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response	23
Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients	23
Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner	23
Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer	23
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers	23
Alternol triggers immunogenic cell death via reactive oxygen species generation	23
Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients	22
IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation	22
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression	22
Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML	22
Cross-reactivity between cancer and microbial antigens	22
Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma	22
T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer	22
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors	22
Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis	21
Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis	21
PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer	21
Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma	21
Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy	21
Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients	21
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction	21
Early changes in the immune microenvironment of oral potentially malignant disorders reveal an unexpected association of M2 macrophages with oral cancer free survival	21
Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy	21
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma	21
Immunological alternation in COVID-19 patients with cancer and its implications on mortality	20
DIMEimmune: Robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles	20
Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils	20
PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells	20
Immunotherapy approaches for the treatment of diffuse midline gliomas	20
Immunostimulatory effects of vitamin B5 improve anticancer immunotherapy	20
Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells	20
Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer	20
MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer	20
Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma	19
Dissecting the heterogeneity of the microenvironment in primary and recurrent nasopharyngeal carcinomas using single-cell RNA sequencing	19
Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents	19
Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice	19
Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation	19
Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer	19
T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production	19
An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy	19
Fibroblasts and macrophages cooperate to create a pro-tumorigenic and immune resistant environment via activation of TGF-β/IL-6 pathway in neuroblastoma	19
Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma	19
MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy	18
PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells	18
Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy	18
A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes	18
T and NK cell abundance defines two distinct subgroups of renal cell carcinoma	18
Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors	18
CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2	18
B-cell clusters at the invasive margin associate with longer survival in early-stage oral-tongue cancer patients	18

Trial watch: Toll-like receptor ligands in cancer therapy	18
Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers	18
Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation	17
Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients	17
Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding	17
M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance	17
Anti-Ly6G binding and trafficking mediate positive neutrophil selection to unleash the anti-tumor efficacy of radiation therapy	17
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody	17
Primary tumors from mucosal barrier organs drive unique eosinophil infiltration patterns and clinical associations	17
Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies	17
A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1	17